Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide.
Rosar F, Dewes S, Ries M, Schaefer A, Khreish F, Maus S, Bohnenberger H, Linxweiler J, Bartholomä M, Ohlmann C, Ezziddin S. Rosar F, et al. Among authors: linxweiler j. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):687-694. doi: 10.1007/s00259-019-04674-0. Epub 2020 Jan 3. Eur J Nucl Med Mol Imaging. 2020. PMID: 31901103
Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management.
Linxweiler J, Sprenk J, Cascetta K, Pryalukhin A, Hölters S, Zeuschner P, Nini A, Al-Kailani Z, Ezziddin S, Bohle RM, Fries P, Ohlmann CH, Heinzelbecker J, Siemer S, Stöckle M, Junker K, Saar M. Linxweiler J, et al. J Urol. 2021 Jul;206(1):88-96. doi: 10.1097/JU.0000000000001697. Epub 2021 Feb 22. J Urol. 2021. PMID: 33617326
Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy.
Rosar F, Hau F, Bartholomä M, Maus S, Stemler T, Linxweiler J, Ezziddin S, Khreish F. Rosar F, et al. Among authors: linxweiler j. Theranostics. 2021 Feb 16;11(9):4050-4060. doi: 10.7150/thno.56211. eCollection 2021. Theranostics. 2021. PMID: 33754047 Free PMC article.
Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy.
Khreish F, Wiessner M, Rosar F, Ghazal Z, Sabet A, Maus S, Linxweiler J, Bartholomä M, Ezziddin S. Khreish F, et al. Among authors: linxweiler j. Biomolecules. 2021 Jul 26;11(8):1099. doi: 10.3390/biom11081099. Biomolecules. 2021. PMID: 34439768 Free PMC article.
177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S, Linxweiler J, Bartholomä M, Ezziddin S. Khreish F, et al. Among authors: linxweiler j. Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):1075-1085. doi: 10.1007/s00259-021-05525-7. Epub 2021 Sep 7. Eur J Nucl Med Mol Imaging. 2022. PMID: 34494131 Free PMC article.
60 results